Several leading In Vitro Diagnostic (IVD) companies have posted their first-quarter results for 2026, showing mixed performance across revenue, profitability, and cash flow.

It can be seen from analysis on major blood grouping analyzer-related patent applications published in the 3 years from 2018 to 2021 that benefited from the basically stable original technologies of the industry; domestic enterprises have continuously increased R&D inputs, constantly improved technical innovation capability, made breakthroughs in many technologies, and developed a batch of core components of instruments with independent intellectual property rights through follow-on R&D strategy.

NEW YORK Personalis reported after the close of the market on Wednesday that its fourth quarter revenues rose 38 percent year over year, driven by an increase in testing volume and analytical services provided to the US Department of Vetera

NEW YORK Oncocyte said after the close of the market on Wednesday that its fourth quarter net loss rose 77 percent year over year as it pushed toward a transition to commercial test operations. For the three-month period ended Dec. 31, 2019

NEW YORK Biocept said after the close of the market on Wednesday that its fourth quarter revenues more than doubled year over year, driven by 46 percent growth in commercial test volume and 34 percent growth in average insurance reimburseme

NEW YORK HTG Molecular Diagnostics reported after the close of the market on Wednesday an 11 percent year-over-year drop in its full-year revenues, driven by a significant decrease in collaboration revenue. For the year ended Dec. 31, 2019,

FDA has been working closely with other government agencies and academic centers that are investigating the use of the drug chloroquine to determine whether it can be used to treat patients with mild-to-moderate COVID-19 to potentially redu

NEW YORK Quidel said after the close of the market on Wednesday that it has received expanded Emergency Use Authorization from the US Food and Drug Administration for the Lyra SARS-CoV-2 assay. Under the expanded EUA, the assay can now be u

Novartis announced in a March 20, 2020 press release that it is committing to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and a related drug, chloroquine,

FDA announced that the agency will temporarily postpone all domestic routine surveillance facility inspections, those conducted every few years based on a risk analysis. In a March 18, 2020 statement, FDA Commissioner Stephen M. Hahn said t

Abbott Laboratories, one of the biggest players in the medical device space, has obtained Emergency Use Authorization for a test to detect the coronavirus [COVID-19]. The Abbott Park, IL-based company joins the rapidly expanding list of com

The Association of the British Pharmaceutical Industry (ABPI) has issued a statement noting that it shares the ambition of the United Kingdoms government, as set out in its published approach to the negotiations for the future relationship